You are browsing the archive for ARCH Venture Partners - peHUB.

Ikaria to Pay Out $172M Dividend to Shareholders, including New Mountain: UPDATED

Posted on: September 6, 2012 by Luisa BeltranNo Comments »

New Mountain will be getting more money back. But this time it’s Ikaria that’s paying out a $172 million dividend.

Siluria Raises $30M From Bright, Vulcan, Kleiner, ARCH, Alloy, Others

Posted on: July 26, 2012 by Mark BosletNo Comments »

Siluria Technologies said it closed a $30 million Series C financing led by new investors Bright Capital and Vulcan Capital and joined by existing investors ARCH Venture Partners, The Wellcome Trust, Alloy Ventures, Kleiner Perkins Caufield and Byers, Lux Capital, Altitude Life Science Ventures and Presidio Ventures. The company is developing a technology to convert [...]

W Fund Officially Launches to Invest in Washington-Based Start-ups

Posted on: June 21, 2012 by Connie LoizosNo Comments »

Seattle-based W Fund, a $20 million, university-focused  fund that officially closed on May 31, officially launched today, according to its managing directors. The fund aims to back startups spun out of the University of Washington and other state research institution and its decisions will be made by an investment committee that Tom Alberg and Greg [...]

Hot Venture Funds From 2007 And 2008 Suggest Good Vintages: Slideshow

Posted on: May 14, 2012 by Mark Boslet1 Comment »

Venture capital returns have begun to recover with exits from companies such as LinkedIn, Zynga, Jive Software and Imperva fueling liquidity. Funds from 2007 and 2008 are good examples of the renewal.

Fate Therapeutics Appoints chairman and interim CEO

Posted on: December 15, 2011 by asormaniNo Comments »

San Diego headquartered biotech company Fate Therapeutics has appointed William H. Rastetter as chairman and interim CEO. Rastetter is also a partner in venture capital firm Venrock. Fate Therapeutics has secured venture backing from OVP Venture Partners, Astellas Venture Management, Genzyme Ventures, ARCH Venture Partners, Polaris Venture Partners and Venrock. PRESS RELEASE Fate Therapeutics, Inc. [...]

Groove Biopharma Raises $6 Mln

Posted on: December 12, 2011 by Luisa BeltranNo Comments »

Groove Biopharma has raised $6 million in series B financing from Alexandria Venture Investments, ARCH Venture Partners, OVP Venture Partners, Versant Ventures, and WRF Capital. Seattle-based Groove Biopharma is a privately held biotech.

Avatar of cnolan

by cnolan

Agios Pharmaceuticals Seals $78M Series C

Posted on: November 17, 2011 by cnolanNo Comments »

Agios Pharmaceuticals, a Cambridge, Mass.-based developer of drugs to treat cancer, has sealed a whopping $78 million in fresh capital. The company did not disclose all investors in the Series C round, but said that publicly traded Celgene participated, as did existing backers ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Adesto Technologies Closes Third Round Led By Altis Semiconductor

Posted on: October 25, 2011 by PEHub AdministratorNo Comments »

Adesto Technologies, a Sunnyvale-based, venture-backed semiconductor company specializing in conductive bridging RAM or CBRAM technology, has raised an undisclosed amount of financing — its third round — led by Altis Semiconductor. The companies current investors, which include Adams Street Partners, ATA Ventures, and Arch Venture Partners, among others, contributed pro-rata in the new round. PRESS RELEASE: [...]

Siluria Technologies Nets $20M

Posted on: September 28, 2011 by PEHub AdministratorNo Comments »

Siluria Technologies, the California-based methane conversion company, has landed $20 million in the form of a Series B investment led by the Wellcome Trust, a UK-based foundation. Other investors include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.

Avatar of cnolan

by cnolan

Siluria Technologies Closes on $20M

Posted on: September 27, 2011 by cnolan1 Comment »

Siluria Technologies, a San Francisco-based developer of methane-based alternatives for producing fuels and chemicals normally derived from oil, has raised $20 million in new capital. The Series B round was led by UK-based Wellcome Trust, with participation from Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.